Entest BioMedical Inc. Stock Price - ENTB

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Ultimate Trader (Monthly)
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN
Entest Biomedical Inc. (PC) ENTB Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  +0.0001 +0.26% 0.038 0.038 0.024 0.038 0.0379 16:23:33
Bid Price Ask Price Spread Spread % News
0.0024 0.038 0.0356 93.68% - -
Stock Trades Traded Volume Average Volume 52 Week Range
8 36,402 32.37k 0.02 - 0.06
Last Trade Time Type Quantity Stock Price Currency
15:51:17 7,500 $0.04 USD

Entest Biomedical Inc. (PC) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 1.87M 49.17M $ -506.69k - -3.69 17.04M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Entest Biomedical Inc. (PC) News

Latest ENTB Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ENTB Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.03640.0380.0220.0380042k15k0.00164.40%
1 Month0.031250.040.019650.03630290k35k0.0067521.60%
3 Months0.0340.040.0150.03540290k34k0.00411.76%
6 Months0.0330.040.0150.03230495k42k0.00515.15%
1 Year0.04650.05590.0150.040102M75k-0.0085-18.28%
3 Years0.00010.09190.00010.00130113M2M0.037937,900.00%
5 Years0.00120.09190.00010.00110293M9M0.03683,066.67%

Entest Biomedical Inc. (PC) Description

Entest BioMedical, Inc. is a biotechnology company dedicated to developing treatments that harness the body's own reparative/immunological mechanisms. The Company is currently developing Immuno-Therapeutic Cancer Vaccines for dogs. The Company sees applications for its areas of focus in beyond animal venues to human applications. The Company has adopted a veterinary first approach, believing once efficacy in animals is established and near term revenue achieved, viability in transitioning to human applications can be made via joint ventures and license agreements.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.